Detailed Narrative
Strong Q2 FY25 Performance Driven by Pharma
Hikal reported a robust Q2 FY25 with revenue reaching INR 453 crores, marking a 29% growth both year-on-year and quarter-on-quarter. EBITDA for the quarter stood at INR 75 crores, a 30% increase, with the EBITDA margin improving to 16.5% from 13.2% in the prior year. This performance was primarily fueled by improved volume offtake in the Pharmaceutical business and stable raw material prices, contributing to cost improvements.
Pharmaceutical Business Momentum Continues
The Pharmaceutical business was a key growth driver, reporting Q2 FY25 revenue of INR 294 crores and EBIT of INR 40 crores. The EBIT saw a significant increase of 934 basis points year-on-year and 994 basis points quarter-on-quarter. Management expects this positive momentum to continue into H2 FY25, with Q3 anticipated to be subdued due to customer year-end effects, but a strong bounce back projected for Q4. The CDMO segment within Pharma now accounts for close to 40% of the division's total revenue, with a healthy pipeline of early-stage NCE products.
Crop Protection Sector Stabilizing Amidst Challenges
The Crop Protection division recorded INR 159 crores in revenue for Q2 FY25, with an EBIT of INR 8 crores and an EBIT margin of 5%. While volumes grew by 22% in Q2, value degrew by 4% due to pricing pressure. Management indicated that the sector is showing signs of stabilization, with excess inventory issues gradually resolving. However, a full positive momentum of growth is still 2 to 3 quarters away, with significant improvements expected by H2 FY26.
Animal Health and CDMO Pipeline Progress
Hikal's Animal Health facility has successfully validated six products, with regulatory filings underway, and commercial sales expected to commence within the next 12 months. In the CDMO segment, two advanced intermediate projects for new chemical entities are in Phase 3 clinical trials, with ramping up expected to begin in 2026-2027. The company is also evaluating GLP-1 inhibitors, indicating a focus on expanding its product portfolio in the diabetic segment.
Financial Health and Capital Allocation
The company successfully reduced its working capital by INR 50 crores in H1 FY25, improving cash flow. Current year debt is expected to be around INR 800 crores, with a repayment of INR 130 crores planned for FY25-26, maintaining debt levels in the same range. Capex for new capacity, primarily in Pharma, is expected to come on stream next year and commercialize over 1-2 years. Hikal continues to allocate 4-5% of its revenue to R&D, fostering innovation and maintaining a differentiated technology toolbox.
Strategic Focus on New Customer Acquisition and Operational Efficiency
Hikal's strategic focus includes onboarding new customers, acquiring new projects, and enhancing operational efficiencies. The company is expanding its global presence by onshoring people in North America, Europe, and Japan, and setting up an office in Latin America to get closer to customers. This proactive approach aims to capitalize on the 'China + 1' strategy and opportunities arising from initiatives like the BIOSECURE Act, particularly from US innovators.